Author

E. C. Dreaden

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:deep learning· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1

Frequent Co-Authors

C. C. Porter· 4 shared P. Do· 4 shared C. J. Henry· 3 shared L. A. Birnbaum· 3 shared A. Chyong· 2 shared B. Uricoli· 2 shared D. DeRyckere· 2 shared D. K. Graham· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioengineering

C. C. Porter

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

The T-cell niche tunes immune function through modulation of the cytoskeleton and TCR-antigen forces

A. V. Kellner, R. Hunter, P. Do, J. Eggert, M. Jaffe, D. K. Geitgey, M. Lee, J. A. G. Hamilton, A. J. Ross, R. S. Ank, R. L. Bender, R. Ma, C. C. Porter, E. C. Dreaden, B. B. Au-Yeung, , K. Salaita

This study shows that the adipocyte niche impairs T-cell function by modulating cytoskeletal dynamics and reducing TCR-antigen forces in both mice and human T-cells.

bioRxiv · Jan 31, 2024 · PreprintBioengineering

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

J. M. Kelvin, J. Jain, A. Thapa, M. Qui, L. A. Birnbaum, S. G. Moore, H. Zecca, R. J. Summers, E. Costanza, B. Uricoli, X. Wang, N. T. Jui, H. Fu, Y. Du, D. DeRyckere, , E. C. Dreaden

The paper develops a nanoscale combination drug formulation targeting MERTK, FLT3, and BCL-2 to treat AML, showing improved synergistic responses in vitro and in patient samples.

bioRxiv · Mar 13, 2023 · PreprintBioengineering

Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines

L. A. Birnbaum, E. C. Sullivan, P. Do, B. Uricoli, C. C. Porter, C. J. Henry, E. C. Dreaden

This paper develops a method to control cytokine activity using light, enabling spatial and temporal regulation of immune responses ex vivo.

bioRxiv · Oct 3, 2022Bioengineering

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia

J. M. Kelvin, D. Y. Zhang, E. K. Williams, S. G. Moore, L. A. Birnbaum, H. Zecca, X. Wang, J. Jain, M. Qui, N. T. Jui, H. Fu, Y. Du, M. L. Kemp, W. A. Lam, D. DeRyckere, , E. C. Dreaden

The paper identifies synergistic drug combinations for T-ALL using high-throughput screens and develops lipid nanoparticle formulations that maintain drug synergy and improve anti-leukemic activity.

bioRxiv · Sep 21, 2022 · PreprintBioengineering

Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia

P. Do, L. A. Perdue, A. Chyong, R. Hunter, J. Dougan, C. J. Henry, C. C. Porter, E. C. Dreaden

This paper develops a method to rapidly assemble and screen multivalent immune cell-redirecting therapies for leukemia, identifying compounds with lytic activity comparable to existing treatments.

bioRxiv · May 8, 2020Bioengineering

Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency

L. A. Perdue, P. Do, C. David, A. Chyong, A. Kellner, A. Ruggieri, H. R. Kim, K. Salaita, G. B. Lesinski, C. C. Porter, E. C. Dreaden

This paper develops a method to control cytokine signaling using light-activated polymers that induce latency and release cytokines on demand.

bioRxiv · Feb 13, 2020Bioengineering